WALTHAM, Mass., June 7 /PRNewswire-FirstCall/ -- Inverness
Medical Innovations, Inc. (NYSE: IMA) announced today that it has
further extended its offer to exchange up to $100,000,000 in aggregate principal amount of
7.875% Senior Notes due 2016 (the "Notes") that have been
registered under the Securities Act of 1933, as amended, for a like
principal amount of its outstanding unregistered 7.875% Senior
Notes due 2016, to 5:00 p.m.,
New York City time, on
Friday, June 11, 2010, unless further
extended.
The terms and conditions of the exchange offer are set forth in
Inverness's prospectus dated April 21,
2010.
The exchange offer had been scheduled to expire at 5:00 p.m., New York
City time, on Friday, June 4,
2010. Inverness has been advised that, as of that
time, $98,000,000 in aggregate
principal amount, or approximately 98% of the aggregate principal
amount, of outstanding unregistered 7.875% Senior Notes due 2016
had been validly tendered to the exchange agent by the holders
thereof, including by means of guaranteed delivery.
The exchange agent for the offer is The Bank of New York Mellon
Trust Company, N.A., Corporate Trust Operations, Reorganization
Unit, 101 Barclay Street — 7 East, New
York, NY 10286, Attn: Carolle
Montreuil, (212) 815-5920.
This press release shall not constitute an offer to sell or the
solicitation of an offer to buy any securities, nor shall there be
any sale of securities in any jurisdiction in which such offer,
solicitation or sale would be unlawful prior to registration or
qualification under the securities laws of any such
jurisdiction.
Important Additional Information and Where to Find It
Inverness and its guarantor subsidiaries have filed with the
SEC, and the SEC has declared effective, a Registration Statement
on Form S-4 containing a Prospectus and other documents relating to
the exchange offer. Holders of unregistered notes are urged to read
carefully the Prospectus, any amendments or supplements thereto and
any other relevant documents filed with the SEC when available
because they contain important information. Holders of unregistered
notes will be able to obtain free copies of the Registration
Statement, the Prospectus, any amendments or supplements thereto
and other documents filed with the SEC by Inverness and its
guarantor subsidiaries, when they become available, through the web
site maintained by the SEC at www.sec.gov. Holders of
unregistered notes will also be able to obtain free copies of the
Registration Statement, the Prospectus and any amendments or
supplements thereto, when they become available, from Inverness by
requesting them in writing at Inverness Medical Innovations, Inc.,
51 Sawyer Road, Suite 200, Waltham,
Massachusetts, 02453, telephone (781) 647-3900,
Attention: Secretary.
The exchange offer will only be made pursuant to the Prospectus,
the letter of transmittal and other offering documents initially
filed with the SEC on March 1, 2010,
as amended or supplemented. The exchange offer is scheduled to
expire at 5:00 p.m., New York City time, on June 11, 2010, unless further extended. If the
exchange offer is further extended, Inverness will notify the
exchange agent for the offer and issue a press release announcing
the extension on or before 9:00 a.m.
New York City time on the first
business day following the date the exchange offer was scheduled to
expire.
Forward Looking Statements
This press release may contain forward-looking statements within
the meaning of the federal securities laws. These statements
reflect Inverness' current views with respect to future events and
are based on management's current assumptions and information
currently available. Actual results may differ materially due to
numerous factors including the risks and uncertainties described in
Inverness' Annual Report on Form 10-K/A for the year ended
December 31, 2009, and other factors identified from time to
time in its filings with the Securities and Exchange Commission.
Inverness undertakes no obligation to update any forward-looking
statements contained herein.
SOURCE Inverness Medical Innovations, Inc.